Key facts
- It has raised $380K; the latest was Early Stage VC ($380K) in Apr 2025.
- Notable investors include Innovatiefonds Noord-Holland, Amsterdam Academic Ventures, Netherlands Organisation for Scientific Research (Netherlands), UvA Ventures Holding.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Parkinnova Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Parkinnova Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Parkinnova Therapeutics
Operator of a therapeutic research center intended to find treatments for Parkinson's disease. The company aims to develop a sustainable and effective treatment, enabling patients to live their lives to the fullest, free from the burden of motor symptoms and limitations.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2024
- Employees
- 3
- Website
- parkinnova.com/
- Ownership
- Privately Held (backing)
Parkinnova Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Parkinnova Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Parkinnova Therapeutics in its N-PORT filings yet. We sweep new filings monthly.